Studies a subcutaneous drug for advanced Parkinson disease in Belgium
Checks how well foslevodopa/foscarbidopa works for adults with advanced Parkinson disease.
Plain-language title generated from the registry record
Registry title: A Study to Assess Change in Disease Symptoms in Adult Participants With Advanced Parkinson Disease Using Subcutaneous Foslevodopa/Foscarbidopa in Belgium
Key facts
- Where
- Bonheiden, Bruges, Edegem, Ghent, Hasselt, Kortrijk, La Louvière, Leuven, Ostend, Roeselare, and Tournai, BelgiumSee the 12 sites
Where in Belgium
- Imelda Ziekenhuis /ID# 279436Bonheiden, BelgiumTaking people
- Algemeen Ziekenhuis Sint-Jan Brugge /ID# 279422Bruges, BelgiumTaking people
- Universitair Ziekenhuis Antwerpen /ID# 279434Edegem, BelgiumTaking people
- AZ Sint-Lucas /ID# 279453Ghent, BelgiumTaking people
- UZ Gent /ID# 279433Ghent, BelgiumTaking people
- Jessa Ziekenhuis - Campus Virga Jesse /ID# 279454Hasselt, BelgiumTaking people
- Az Groeninge Campus Kennedylaan /ID# 279423Kortrijk, BelgiumTaking people
- Chu Tivoli /ID# 279455La Louvière, BelgiumTaking people
- Universitair Ziekenhuis Leuven /ID# 279439Leuven, BelgiumTaking people
- AZ Oostende /ID# 279461Ostend, BelgiumTaking people
- AZ-Delta. /ID# 279437Roeselare, BelgiumTaking people
- Centre Hospitalier De Wallonie Picarde - Site Notre Dame /ID# 279452Tournai, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AbbVie
- Trial code
- NCT07382440
- Record updated
- 10 July 2026
- Original description
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how effective Foslevodopa/Foscarbidopa is in treating adult participants with advanced Parkinson Disease under routine clinical practice in Belgium.Read full original descriptionShow less
Observational Prospective Study to Evaluate Effectiveness of Subcutaneous Treatment With Foslevodopa/Foscarbidopa in Real Life Setting for Advanced Parkinson's Disease Patients in Belgium.
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how effective Foslevodopa/Foscarbidopa is in treating adult participants with advanced Parkinson Disease under routine clinical practice in Belgium.
Foslevodopa/Foscarbidopa is an approved drug for the treatment of Parkinson's Disease. Approximately 120 adult participants who are prescribed Foslevodopa/Foscarbidopa by their doctors will be enrolled at 15 sites across Belgium.
Participants will receive Foslevodopa/Foscarbidopa subcutaneous infusion as prescribed by their physician. Participants will be followed for up to 18 months.
There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Inclusion: Participant diagnosed with Advanced Parkinson's Disease (PD), aged 18 years or older able to provide voluntary informed consent; Participant evaluated for commercially available continuous subcutaneous Foslevodopa/Foscarbidopa (LDp/CDp) in the hospital at the clinician's discretion as part of his/her routine clinical care and the intention to administer subcutaneous LDp/CDp made prior to and independent of recruitment into the study.
Exclusion: Participant participating in an interventional research study (not including noninterventional studies) during the administration of LDp/CDp; Participant evaluated for commercially available continuous subcutaneous LD/CDp outside of the hospital.